This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

This study has been completed.
Information provided by (Responsible Party):
Kadmon Corporation, LLC Identifier:
First received: September 11, 2007
Last updated: January 26, 2015
Last verified: January 2015
To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.

Condition Intervention Phase
Raynaud's Disease Drug: SLx-2101 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.

Resource links provided by NLM:

Further study details as provided by Kadmon Corporation, LLC:

Primary Outcome Measures:
  • Raynaud's condition scores after 14 days of SLx-2101 [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Safety and tolerability [ Time Frame: 14 days ]

Enrollment: 17
Study Start Date: June 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: SLx-2101
Placebo Comparator: 2
Matching Placebo Dose
Drug: Placebo

Detailed Description:
  1. Number and cumulative duration of Raynaud's attacks.
  2. Adverse events and changes in vital signs.
  3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to Cmax (tmax), and accumulation ratio

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male and female ages 18 and 65 y.o.
  • BMI Body weight within a body mass index range of 17 - 30 kg/m2 (inclusive).

Exclusion Criteria:

  • Hypersensitivity to the active substance of SLx-2101or to any of the excipients.
  • Past or present disease that is judged by the Investigator to have the potential to interfere with the study procedures, compromise safety, or affect the pharmacokinetic and pharmacodynamic evaluations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00528242

University des Saarlandes
Homburg, Germany
Sponsors and Collaborators
Kadmon Corporation, LLC
Study Director: M Baumaker, MD University des Saarlandes
  More Information

Responsible Party: Kadmon Corporation, LLC Identifier: NCT00528242     History of Changes
Other Study ID Numbers: SLx-2101-07-04
Study First Received: September 11, 2007
Last Updated: January 26, 2015

Additional relevant MeSH terms:
Raynaud Disease
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on August 21, 2017